StockNews.com Lowers Can-Fite BioPharma (NYSE:CANF) to Sell

Can-Fite BioPharma (NYSE:CANF) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Separately, EF Hutton Acquisition Co. I upgraded Can-Fite BioPharma to a “strong-buy” rating in a research note on Wednesday, July 17th.

Can-Fite BioPharma Trading Up 2.4 %

NYSE CANF traded up $0.06 during trading hours on Monday, reaching $2.52. 51,782 shares of the company traded hands, compared to its average volume of 65,757. The company has a 50 day moving average of $2.27 and a two-hundred day moving average of $2.48. The stock has a market capitalization of $8.92 million, a PE ratio of -1.41 and a beta of 1.41. Can-Fite BioPharma has a 12 month low of $1.81 and a 12 month high of $4.69.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.